Table 1.
Patient background.
| Characteristics | Total patients n = 33 |
N group n = 11 |
No-N group n = 22 |
p |
|---|---|---|---|---|
| Age (years) | 75.91 ± 8.72 | 80.54 ± 5.76 | 73.59 ± 9.11 | 0.045 |
| Sex | 0.228 | |||
| Female/male | 7/26 | 1/10 | 6/16 | |
| Smoking history | 0.097 | |||
| No/yes | 9/24 | 1/10 | 8/14 | |
| Baseline ILD | 0.097 | |||
| No IPF/IPF | 9/24 | 1/10 | 8/14 | |
| Baseline HRCT pattern | ||||
| UIP + probable | 1.000 | |||
| UIP/fibrotic NSIP | 30/3 | 10/1 | 20/2 | |
| Prior treatment (pirfenidone) | 0.376 | |||
| No/yes | 28/5 | 8/3 | 20/2 | |
| Prior treatment (prednisolone) | 0.798 | |||
| No/yes | 29/4 | 10/1 | 19/3 | |
| %FVC (%) |
71.15 ± 19.54 n = 24 |
76.02 ± 16.46 n = 10 |
67.68 ± 21.37 n = 14 |
0.313 |
| %DLco (%) |
33.44 ± 13.58 n = 19 |
30.78 ± 6.97 n = 9 |
35.84 ± 17.64 n = 10 |
0.434 |
| Serum markers at the diagnosis of AE-IPF | ||||
| P/F ratio | 239.41 ± 102.75 | 236.26 ± 31.4710.30 | 240.98 ± 22.25 | 0.903 |
| WBC (/µL) | 11,241.29 ± 3528.61 | 10,834.50 ± 4366.50 | 11,465.00 ± 799.59 | 0.642 |
| CRP (mg/dL) | 9.32 ± 7.33 | 6.89 ± 6.30 | 10.65 ± 7.66 | 0.176 |
| D-dimer (µg/mL) | 7.77 ± 11.65 | 5.80 ± 4.51 | 8.81 ± 14.06 | 0.517 |
| LDH (U/L) | 360 ± 896.97 | 310 ± 61.56 | 387 ± 103.21 | 0.032 |
| KL-6 (U/L) |
1339.61 ± 786.31 n = 31 |
1253.09 ± 240.32 n = 11 |
1387.20 ± 916.61 n = 20 |
0.657 |
| SP-D (mg/dL) |
491.01 ± 370.36 n = 29 |
516.17 ± 436.08 n = 10 |
475.64 ± 336.75 n = 19 |
0.780 |
ILD interstitial lung disease, IPF idiopathic pulmonary fibrosis, UIP usual interstitial pneumonia, HRCT high resolution computed tomography, NSIP non-specific interstitial pneumonia, AE acute exacerbation of idiopathic pulmonary fibrosis, FVC forced vital capacity, DLco diffusing capacity for carbon monoxide, P/F ratio PaO2/FiO2 ratio, WBC white blood cell, CRP c-related peptide, LDH lactate dehydrogenase, KL-6 Krebs von den Lungen-6, SP-D surfactant protein-D.